MAPT and Alzheimer disease: Within cNEUPRO, Welge et al. reported a sensitivity and specificity of 88% in the discrimination of AD subjects from other dementias and from elderly depressed individuals with cognitive complaints, by combining the measurement of Aβ1-40, Aβ1-38, and phospho-tau [34].